HC Wainwright Reiterates “Buy” Rating for Aprea Therapeutics (NASDAQ:APRE)

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.80) EPS, Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($1.39) EPS, FY2025 earnings at ($0.58) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.68) EPS and FY2028 earnings at ($0.69) EPS.

Aprea Therapeutics Stock Up 10.2 %

Shares of Aprea Therapeutics stock opened at $6.69 on Tuesday. The company has a market cap of $25.02 million, a PE ratio of -1.68 and a beta of 1.05. Aprea Therapeutics has a 52 week low of $2.78 and a 52 week high of $8.85. The business has a 50 day moving average price of $6.39 and a 200-day moving average price of $5.01.

Insider Transactions at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger bought 6,860 shares of Aprea Therapeutics stock in a transaction dated Wednesday, March 13th. The stock was bought at an average cost of $7.29 per share, with a total value of $50,009.40. Following the completion of the acquisition, the director now directly owns 33,685 shares in the company, valued at approximately $245,563.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 9,870 shares of company stock valued at $71,952 over the last ninety days. 20.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aprea Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of APRE. BNP Paribas Arbitrage SNC bought a new position in Aprea Therapeutics during the third quarter valued at $40,000. Millennium Management LLC grew its holdings in Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after purchasing an additional 43,293 shares during the period. Jane Street Group LLC bought a new position in Aprea Therapeutics during the second quarter valued at $54,000. Geode Capital Management LLC bought a new position in shares of Aprea Therapeutics in the second quarter worth $74,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Aprea Therapeutics by 76.4% in the third quarter. Vanguard Group Inc. now owns 27,341 shares of the company’s stock worth $114,000 after acquiring an additional 11,840 shares during the period. 34.19% of the stock is owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.